Issues of concern and development of classifications of the main parameters of therapy quality and compliance. Part III: quality of pharmacotherapy

This article is the third work in a series of publications on consideration of the main parameters of therapy quality and compliance and the development of their classifications. The aim is to determine, based on scientific literature data, the main parameters reflecting the quality of therapy and to develop their classification.

According to the World Health Organization, more than half of all drugs are prescribed and sold improperly, and half of all patients take their medications inadequately. To date, there is no generally accepted terminology and classification regarding the quality of therapy. The closest synonym for this concept is "rational/irrational pharmacotherapy". There are special scales and lists of criteria that reflect the quality of prescribed therapy and can be used to assess it. The main parameters of pharmacotherapy quality are the effectiveness and safety of treatment; some lists also include medication adherence. Data on the effectiveness and safety of drugs with proven efficacy for a certain disease are available in clinical guidelines. Information on aspects of drug safety is usually most fully presented in official instructions for medical products, which, along with clinical guidelines, are the main supporting documents in determining the quality parameters of pharmacotherapy. Also, a number of indices have been developed for the quantitative assessment of pharmacotherapy quality, both special (for certain diseases) and universal.

Based on the identified main parameters of pharmacotherapy quality, effectiveness and safety, as well as the subcategories of these parameters, we developed a classification.

The proposed classification of pharmacotherapy quality parameters can be used as a "roadmap" in prescription of pharmacotherapy and contribute to increasing its effectiveness, safety, personalization, i.e. pharmacotherapy quality in general. This will ultimately make it more likely to achieve the main goals of this treatment in real-world practice.

1. Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Problematic issues and development of classifications of the main parameters of quality and adherence to pharmacotherapy. Part I: Patient adherence to treatment. Cardiovascular Therapy and Prevention. 2023;22(6):3603. (In Russ.) doi:10.15829/1728-8800-2023-3603.

2. Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Problematic issues and development of classifications of the main parameters of quality and adherence to pharmacotherapy. Part II: Patient adherence to treatment. Cardiovascular Therapy and Prevention. 2024;23(2):3920. (In Russ.) doi:10.15829/1728-8800-2024-3920.

3. Jones DS, Greene JA. The decline and rise of coronary heart disease: understanding public health catastrophism. Am J Public Health. 2013;103(7):1207-18. doi:10.2105/AJPH.2013.301226.

4. Pollock M, Bazaldua OV, Dobbie AE. Appropriate prescribing of medications: an eight-step approach. Am Fam Physician. 2007; 75(2):231-6.

5. Basger BJ, Moles RJ, Chen TF. Development of an aggregated system for classifying causes of drug-related problems. Ann Pharmacother. 2015;49(4):405-18. doi:10.1177/1060028014568008.

6. Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Evidence-based pharmacotherapy in cardiology. National guideline. Rational Pharmacotherapy in Cardiology. 2024;20(1):105-70. (In Russ.) doi:10.20996/1819-6446-2024-2992.

7. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-81. doi:10.1111/jgs.18372.

8. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-32. doi:10.1007/s41999023-00777-y.

9. Pazan F, Weiss C, Wehling M; FORTA Expert Panel Members. The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults. Drugs Aging. 2023;40(5):417-26. doi:10.1007/s40266-023-01024-6.

10. Cooper JA, Ryan C, Smith SM, et al.; (The PROMPT Steering Group). The development of the PROMPT (PRescribing Optimally in Middle-aged People's Treatments) criteria. BMC Health Serv Res. 2014;14:484. doi:10.1186/s12913-014-0484-6.

11. Pazan F, Kather J, Wehling M. A systematic review and novel classifcation of listing tools to improve medication in older people. Eur J Clin Pharmacol. 2019;75:619-25. doi:10.1007/s00228-019-02634-z.

12. Wehling M, Petrovic M. Deprescribing or represcribing: not just a semantic dilemma. Eur Geriatr Med. 2022;13(3):529-30. doi:10.1007/s41999-021-00583-4.

13. Smaha LA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148(5 Suppl):S46-8. doi:10.1016/j.ahj.2004.09.015.

14. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900. doi:10.1007/s40266013-0118-4.

15. Sychev DA, Sosnovsky EE, Orekhov RE, et al. Contemporarymethods of dealing polypharmacy in elderly and senile patients. Siberian Medical Review. 2016;2:13-21. (In Russ.)

16. El Hadidi S, Darweesh E, Byrne S, et al. A tool for assessment of heart failure prescribing quality: A systematic review and metaanalysis. Pharmacoepidemiol Drug Saf. 2018;27(7):685-94. doi:10.1002/pds.4430.

17. Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26(16):1653-9. doi:10.1093/eurheartj/ehi251.

18. Komajda M, Cowie MR, Tavazzi L, et al.; QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414-23. doi:10.1002/ejhf.887.

19. Zyryanov SK, Fitilev SB, Vozzhaev AV, et al. Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease. Rational Pharmacotherapy in Cardiology. 2021;17(1):29-35. (In Russ.) doi:10.20996/1819-6446-2020-16-08.

20. Suvorov AY, Martsevich SY, Kutishenko NP, et al. The way of assessing the adherence to modern drug therapy clinical guidelines aimed at reducing the risk of recurrent stroke (according to the LIS-2 register). Rational Pharmacotherapy in Cardiology. 2015;11(1):45-52. (In Russ.) doi:10.20996/1819-64462015-11-1-45-52.

21. Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Novel approaches to the comprehensive assessment of the quality and adherence to pharmacotherapy and its use in cardiovascular patients. Cardiovascular Therapy and Prevention. 2023;22(1):3522. (In Russ.) doi:10.15829/1728-88002023-3522.